<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00551655</url>
  </required_header>
  <id_info>
    <org_study_id>COL109413</org_study_id>
    <nct_id>NCT00551655</nct_id>
  </id_info>
  <brief_title>Impact of Drug Therapy and Co-Morbidities on the Development of Renal Impairment in HIV-Infected Patients</brief_title>
  <official_title>Impact of Drug Therapy and Co-Morbidities on the Development of Renal Impairment in HIV-Infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AIDS Arms Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AIDS Arms Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tenofovir (TDF)-containing regimens may be associated with decreasing renal function in
      HIV-infected patients concurrently treated with boosted PI's and/or have co-morbid conditions
      including diabetes mellitus, hypertension, anemia, hepatitis B, and hepatitis C.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      COL109413 is a Phase IV retrospective database study involving the review of medical records
      of approximately 850 HIV-infected patients treated at a single center (Peabody Health Clinic,
      Dallas, Texas) and followed for up to a 4-year period (2003-2006). Patients whose GFR
      decreased &gt;25% from baseline (BL) will be identified and their disease and treatment
      characteristics will be compared to those of patients whose GFR did not change. GFR will be
      calculated by both the MDRD and the Cockcroft-Gault methods.

      The following information will be noted: patient age, weight, gender, race/ethnicity, viral
      load, CD4 cell count, serum creatinine and other available laboratory data, start of HAART
      therapy (TDF - vs non-TDF-containing), changes in drug treatment, co-morbidities
      (hypertension, diabetes mellitus, anemia, hepatitis C virus or hepatitis B virus infection),
      drug treatment for co-morbidities and non-HIV-related illnesses, and adherence by
      prescription refill. The study endpoints will be: time from treatment initiation-to-event
      (GFR decrease &gt;25% from BL) analysis between TDF-containing vs non-TDF-containing
      antiretroviral therapy; number of patients who convert from National Kidney
      Foundation-defined mild to moderate renal impairment or from moderate to severe renal
      impairment in the TDF vs non-TDF-treated patients; effect of co-morbidities and concomitant
      medications on time to GFR decrease &gt;25% from BL.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <enrollment type="Actual">684</enrollment>
  <condition>Human Immunodeficiency Viruses</condition>
  <condition>Kidney Failure</condition>
  <condition>HIV Infections</condition>
  <eligibility>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV positive patients seen between 2003 and 2006

        Exclusion Criteria:

          -  Fewer than two laboratory results
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keith Rawlings, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AIDS Arms Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peabody Health Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Röling J, Schmid H, Fischereder M, Draenert R, Goebel FD. HIV-associated renal diseases and highly active antiretroviral therapy-induced nephropathy. Clin Infect Dis. 2006 May 15;42(10):1488-95. Epub 2006 Apr 11. Review.</citation>
    <PMID>16619164</PMID>
  </reference>
  <reference>
    <citation>Izzedine H, Launay-Vacher V, Deray G. Antiviral drug-induced nephrotoxicity. Am J Kidney Dis. 2005 May;45(5):804-17. Review.</citation>
    <PMID>15861345</PMID>
  </reference>
  <reference>
    <citation>Ross MJ, Klotman PE. HIV-associated nephropathy. AIDS. 2004 May 21;18(8):1089-99.</citation>
    <PMID>15166524</PMID>
  </reference>
  <reference>
    <citation>Guo X, Nzerue C. How to prevent, recognize, and treat drug-induced nephrotoxicity. Cleve Clin J Med. 2002 Apr;69(4):289-90, 293-4, 296-7 passim. Review.</citation>
    <PMID>11996200</PMID>
  </reference>
  <reference>
    <citation>Iglesias JI, Nasr SH, Markowitz GS, D'Agati VD. AIDS, nephrotic-range proteinuria, and renal failure. Kidney Int. 2006 Jun;69(11):2107-10.</citation>
    <PMID>16641932</PMID>
  </reference>
  <reference>
    <citation>Coca S, Perazella MA. Rapid communication: acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity. Am J Med Sci. 2002 Dec;324(6):342-4.</citation>
    <PMID>12495304</PMID>
  </reference>
  <reference>
    <citation>Antoniou T, Raboud J, Chirhin S, Yoong D, Govan V, Gough K, Rachlis A, Loutfy M. Incidence of and risk factors for tenofovir-induced nephrotoxicity: a retrospective cohort study. HIV Med. 2005 Jul;6(4):284-90.</citation>
    <PMID>16011534</PMID>
  </reference>
  <reference>
    <citation>Schaaf B, Aries SP, Kramme E, Steinhoff J, Dalhoff K. Acute renal failure associated with tenofovir treatment in a patient with acquired immunodeficiency syndrome. Clin Infect Dis. 2003 Aug 1;37(3):e41-3. Epub 2003 Jul 22.</citation>
    <PMID>12884188</PMID>
  </reference>
  <reference>
    <citation>Karras A, Lafaurie M, Furco A, Bourgarit A, Droz D, Sereni D, Legendre C, Martinez F, Molina JM. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis. 2003 Apr 15;36(8):1070-3. Epub 2003 Apr 4.</citation>
    <PMID>12684922</PMID>
  </reference>
  <reference>
    <citation>Créput C, Gonzalez-Canali G, Hill G, Piketty C, Kazatchkine M, Nochy D. Renal lesions in HIV-1-positive patient treated with tenofovir. AIDS. 2003 Apr 11;17(6):935-7.</citation>
    <PMID>12660548</PMID>
  </reference>
  <reference>
    <citation>Verhelst D, Monge M, Meynard JL, Fouqueray B, Mougenot B, Girard PM, Ronco P, Rossert J. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis. 2002 Dec;40(6):1331-3.</citation>
    <PMID>12460055</PMID>
  </reference>
  <reference>
    <citation>Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G; National Kidney Foundation. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003 Jul 15;139(2):137-47. Erratum in: Ann Intern Med. 2003 Oct 7;139(7):605.</citation>
    <PMID>12859163</PMID>
  </reference>
  <reference>
    <citation>Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41.</citation>
    <PMID>1244564</PMID>
  </reference>
  <reference>
    <citation>Sokoll LJ, Russell RM, Sadowski JA, Morrow FD. Establishment of creatinine clearance reference values for older women. Clin Chem. 1994 Dec;40(12):2276-81.</citation>
    <PMID>7988015</PMID>
  </reference>
  <reference>
    <citation>Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999 Mar 16;130(6):461-70.</citation>
    <PMID>10075613</PMID>
  </reference>
  <verification_date>October 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2007</study_first_submitted>
  <study_first_submitted_qc>October 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2007</study_first_posted>
  <last_update_submitted>November 5, 2007</last_update_submitted>
  <last_update_submitted_qc>November 5, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2007</last_update_posted>
  <keyword>Human Immunodeficiency Viruses</keyword>
  <keyword>Glomerular Filtration Rate</keyword>
  <keyword>Tenofovir</keyword>
  <keyword>Treatment Experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

